CClinicalTrials.gg
Not yet recruitingNCT07674160Updated Jun 29, 2026

Effect of Simethicone on Colon Preparation During Water Exchange Colonoscopy

An interventional study of Simethicone with PEG and PEG in Quality of Bowel Preparation, sponsored by Dalin Tzu Chi General Hospital. Not yet recruiting. Open to participants aged 20 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Dalin Tzu Chi General Hospital · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Study summary

Background: Colonoscopy reduces colorectal cancer mortality by enabling early detection and removal of adenomas. Its effectiveness, however, depends heavily on bowel preparation quality and mucosal visibility. Simethicone, an anti-foaming agent, decreases intraluminal bubbles and improves visualization; studies in conventional air-insufflation colonoscopy generally show benefits for cleanliness and patient comfort, but evidence in water-exchange (WE) colonoscopy remains limited.Objective: To evaluate whether adding oral simethicone to a split-dose polyethylene glycol (PEG) regimen further improves bowel cleanliness and procedural performance in WE colonoscopy.Methods: Adults undergoing outpatient colonoscopy will be randomly assigned (1:1) to a simethicone group or a control group, with a planned enrollment of 180 participants. All procedures will use the WE insertion technique, and endoscopists will be blinded to group allocation. The primary endpoint is the Boston Bowel Preparation Scale (BBPS); adequate preparation is defined as a total score ≥6 with all segment scores ≥2. Secondary endpoints include bubble score and CEBuS, adenoma detection rate (ADR), polyp detection rate (PDR), cecal intubation rate and time, withdrawal time, volume of water used and flushing/irrigation metrics, and patient-reported tolerability and satisfaction.Expected Results: Compared with PEG alone, adding simethicone is expected to (1) increase the proportion of adequate BBPS preparations, (2) reduce bubble coverage, (3) maintain or potentially improve ADR/PDR, and (4) enhance patient tolerability and satisfaction.Conclusion: If effective, this intervention would provide a simple, low-cost strategy to optimize the quality of WE colonoscopy.

02

Conditions studied

  • Quality of Bowel Preparation

Keywords

  • simethicone
  • Boston Bowel Preparation Scale (BBPS)
  • bubble score
  • Colon Endoscopic Bubble Scale(CEBuS)
  • adenoma detection rate (ADR)
  • water-exchange (WE) colonoscopy
03

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Consecutive patients undergoing screening, surveillance, or diagnostic colonoscopy.
  • Procedures performed by participating endoscopists.
  • Ability to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Colonoscopy performed using air insufflation or water immersion technique.
  • History of colorectal surgery (e.g., colectomy or colostomy).
  • Known or suspected colonic obstruction or severe stricture.
  • Requirement for inpatient bowel preparation.
  • Known allergy or hypersensitivity to simethicone.
  • Unable or unwilling to provide informed consent.
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    Without simethicone group

    follow a bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution.

    Drug: PEG

  • Experimental
    With simethicone group

    Participants received a total of 30 mL of simethicone, with 15 mL added to each 1-liter dose of polyethylene glycol (PEG) solution in the split-dose regimen.

    Drug: Simethicone with PEG

Interventions

  • DrugSimethicone with PEG

    All participants followed a standardized bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution administered in a split-dose regimen. Participants in the simethicone group additionally received 30 mL of simethicone (600 mg), with 15 mL added to each 1-liter dose of PEG solution.

  • DrugPEG

    All participants followed a standardized bowel preparation protocol consisting of 10 mg of bisacodyl and 2 liters of PEG solution administered in a split-dose regimen.

05

What researchers measure

Primary outcomes

  1. Boston bowel preparation scale (BBPS)

    Bowel preparation quality assessed using the Boston Bowel Preparation Scale (BBPS). Adequate preparation is defined as a total score ≥6 with all segment scores ≥2.

    Time frame: At the time of colonoscopy.

Secondary outcomes

  1. Bubble score assessed using a 4-point bubble scale

    Bubble score assessed during colonoscopy using a 4-point scale (0-3) for each colon segment, where higher scores indicate more bubbles.

    Time frame: During the colonoscopy procedure.

  2. Colon Endoscopic Bubble Scale(CEBuS)

    Bowel cleanliness assessed using the Colon Endoscopic Bubble Scale (CEBuS), categorized based on the percentage of mucosal surface obscured by bubbles (e.g., \<5%, 5-50%, \>50%).Higher scores indicate poorer visibility due to bubbles.

    Time frame: During the colonoscopy procedure.

  3. Adenoma detection rate (ADR)

    Time frame: one week

  4. Polyp detection rate (PDR)

    Time frame: one week

  5. Cecal intubation rate

    Proportion of procedures in which the cecum is successfully reached.

    Time frame: At the time of colonoscopy.

  6. Cecal intubation time

    Time from insertion to successful cecal intubation, measured in minutes.

    Time frame: During the colonoscopy procedure.

  7. Withdrawal time

    Time from cecal intubation to scope withdrawal, measured in minutes.

    Time frame: During the colonoscopy procedure.

  8. Volume of water infused

    Total volume of water infused during colonoscopy, measured in milliliters.

    Time frame: During the procedure.

  9. Volume of fluid aspirated

    Total volume of fluid aspirated during colonoscopy, measured in milliliters.

    Time frame: During the procedure

  10. Patient-reported pain score

    Pain assessed using a visual analog scale (VAS) ranging from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: Immediately after the procedure.

  11. Patient satisfaction score

    Patient satisfaction assessed using a numeric rating scale from 0 to 10, where higher scores indicate greater satisfaction.

    Time frame: Immediately after the procedure.

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Tongprasert S, Sobhonslidsuk A, Rattanasiri S. Improving quality of colonoscopy by adding simethicone to sodium phosphate bowel preparation. World J Gastroenterol. 2009 Jun 28;15(24):3032-7. doi: 10.3748/wjg.15.3032. PubMed 19554657 ↗
  • Cao RR, Wang L, Gao C, Pan JH, Yoshida EM, Li HY, Qi XS. Effect of oral simethicone on the quality of colonoscopy: A systematic review and meta-analysis of randomized controlled trials. J Dig Dis. 2022 Mar;23(3):134-148. doi: 10.1111/1751-2980.13084. Epub 2022 Mar 14. PubMed 35075814 ↗
  • Sun M, Yang G, Wang Y. Cleaning effect and tolerance of 16 bowel preparation regimens on adult patients before colonoscopy: a network meta-analysis. Int J Colorectal Dis. 2023 Mar 11;38(1):69. doi: 10.1007/s00384-023-04355-3. PubMed 36905434 ↗
  • Zhang S, Zheng D, Wang J, Wu J, Lei P, Luo Q, Wang L, Zhang B, Wang H, Cui Y, Chen M. Simethicone improves bowel cleansing with low-volume polyethylene glycol: a multicenter randomized trial. Endoscopy. 2018 Apr;50(4):412-422. doi: 10.1055/s-0043-121337. Epub 2017 Nov 13. PubMed 29132175 ↗
  • Joao M, Areia M, Alves S, Elvas L, Brito D, Saraiva S, Cadime AT. The Effect of Oral Simethicone in a Bowel Preparation in a Colorectal Cancer Screening Colonoscopy Setting: A Randomized Controlled Trial. GE Port J Gastroenterol. 2023 Jun 15;31(2):116-123. doi: 10.1159/000530866. eCollection 2024 Apr. PubMed 38572443 ↗
  • Bai Y, Fang J, Zhao SB, Wang D, Li YQ, Shi RH, Sun ZQ, Sun MJ, Ji F, Si JM, Li ZS. Impact of preprocedure simethicone on adenoma detection rate during colonoscopy: a multicenter, endoscopist-blinded randomized controlled trial. Endoscopy. 2018 Feb;50(2):128-136. doi: 10.1055/s-0043-119213. Epub 2017 Oct 6. PubMed 28985630 ↗
  • Moolla M, Dang JT, Shaw A, Dang TNT, Tian C, Karmali S, Sultanian R. Simethicone decreases bloating and improves bowel preparation effectiveness: a systematic review and meta-analysis. Surg Endosc. 2019 Dec;33(12):3899-3909. doi: 10.1007/s00464-019-07066-5. Epub 2019 Aug 26. PubMed 31451919 ↗
  • Menees SB, Elliott E, Govani S, Anastassiades C, Judd S, Urganus A, Boyce S, Schoenfeld P. The impact of bowel cleansing on follow-up recommendations in average-risk patients with a normal colonoscopy. Am J Gastroenterol. 2014 Feb;109(2):148-54. doi: 10.1038/ajg.2013.243. PubMed 24496417 ↗
  • Lebwohl B, Kastrinos F, Glick M, Rosenbaum AJ, Wang T, Neugut AI. The impact of suboptimal bowel preparation on adenoma miss rates and the factors associated with early repeat colonoscopy. Gastrointest Endosc. 2011 Jun;73(6):1207-14. doi: 10.1016/j.gie.2011.01.051. Epub 2011 Apr 8. PubMed 21481857 ↗
  • Sharma P, Burke CA, Johnson DA, Cash BD. The importance of colonoscopy bowel preparation for the detection of colorectal lesions and colorectal cancer prevention. Endosc Int Open. 2020 May;8(5):E673-E683. doi: 10.1055/a-1127-3144. Epub 2020 Apr 17. PubMed 32355887 ↗
  • Zauber AG, Winawer SJ, O'Brien MJ, Lansdorp-Vogelaar I, van Ballegooijen M, Hankey BF, Shi W, Bond JH, Schapiro M, Panish JF, Stewart ET, Waye JD. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med. 2012 Feb 23;366(8):687-96. doi: 10.1056/NEJMoa1100370. PubMed 22356322 ↗
  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4. PubMed 33538338 ↗
08

Registry details

Key details

Study ID
NCT07674160
Lead sponsor
Dalin Tzu Chi General Hospital
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Aug 1, 2026 (estimated)
Primary completion
May 1, 2028 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Jun 29, 2026

Study contacts

Chih -Wei Tseng
Contact
cwtseng2@gmail.com
+886-5-2648000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion